Jin Ren, M.D, Ph.D, Facility Manager and PhD Tutor of Center for Drug Safety Evaluation and Research at SIMM. She undertook the construction and toxicology research of Center for Drug Safety Evaluation at shanghai institute of Materia Medica, Chinese Academy of Scineces. She Received Master degree in Pathology from Chinese Medical University, School of Medicine, received Ph. D. degree in Pathology from Hokkaido University School of Medicine in Japan and was followed by 2 years post-doctoral training in Roswell Park Cancer Institute, NY, U.S.A. 

CDSER obtained NMPA GLP certification in 2004, successfully received OECD GLP accreditation on March of 2012 and audited by U.K. authority, MHRA, for a GLP toxicology study on April of 2013. CDSER also obtained full GLP facility audit by FDA authority on Aug.2016. 

Over 100 papers are therefore generated on the Domestic and international famous magazine and published with 80 papers referenced by SCI. Ten international and domestic patents are applied for, over 20 national and regional research projects are undertaken. As one of the editors, she wrote a toxicity and pathology book named as “ATLAS of Toxicological Pathology”. She has trained more than 20 doctoral students. She was employed as a CDE new drug review expert, NMPA GLP a laboratory expert and a member of a council about Chinese society of toxicology and Chinese pharmaceutical association. Now she is a director of Drug toxicity pathology professional board of CPA and a Contributing member of editorial board of Japanese Journal of Toxicity Pathology.

She was granted for the Second Prize of National Scientific and Technological Progress as the first listed owner in 2013, First Prize of science and technology of Chinese pharmaceutical association in 2009. Ho Liang Ho Lee Foundation for scientific and Technological Progress Award (Medical Pharmacy Awards) in 2015. She was accepted both by British Royal College of Pathology and International Toxicity Pathology as a fellow on April of 2013, which has been recognized by international peers. 12th Wu Jieping - Paul Yeung Sum Medical Prize in Medicine, First prize in life chemistry research by Wuxi Pharma Tech, Shanghai leading talent and the Oversea Chinese Nation (Innovation) Contribution Award, Candidate of new century talents project in Jun of 2004 and other honors like National special government allowances, which is forefront in the national field of toxicology studies.

Second Prize of 2013 National Scientific and Technological Progress as the first listed owner

Ho Leung Ho Lee Foundation Scientific and Technological Progress Award 

International Academy of Toxicologic Pathology Fellow in 2013      

The Royal College of Pathologists Fellow in 2013

First prize in science and technology by Chinese Pharmaceutical Association

Wu Jieping - Paul Yeung Sum Medical Prize in Medicine

First prize in life chemistry research by Wuxi PharmaTech 

The 3rd China Pharmaceutical Association-Yiling Biomedical Innovation Award

First Prize of Shanghai Pudong New Area Science and Technology Award 

Honorary Title of National Outstanding Science and Technology Worker

Women of Innovation and woman pace-setter model in Shanghai

2010 Leading talent of Shanghai

Chinese National (innovation) contribution Award

Top 10 overseas Chinese of shanghai 

Outstanding venture by overseas Chinese affairs office of the state council

Model of national women workers

Candidate of new century talents project

National special government allowances

1.Fan L#, Lai RT#, Ma NN, Dong YX, Li Y, Hou L, Wu Q, Lu HL, Qiao JW, Gong LK, Chen J*, Xie Q*, Jin Ren*: miR-552-3p modulates transcriptional activities of FXR and LXR to meliorate hepatic glycolipid metabolism disorder. Journal of Hepatology. Journal of Hepatology. 2021 Jan;74(1):8-19.（IF=20.582）

2.Yang Zhao, Jing Chen, Wenxin Wei, Xinming Qi, Chunzhu Li, and Jin Ren. The dual-inhibitory effect of miR-338-5p on multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduction and Targeted Therapy. 2018 Jan 26;3:3. doi: 10.1038. (IF=13.493)

3.Guo HJ, Pu M, Tai YS, Chen YX, Lu HL, Qiao JW, Wang GH, Chen J, Qi XM, Huang RM*, Tao ZT*, Ren J*. Nuclear miR-30b-5p suppresses TFEB-mediated lysosomal biogenesis and autophagy. Cell Death and Differentiation. 2021 Jan; 28(1):320-336. (IF:10.717)  

4.Yu Li1,2, Huibiao Zhang3 , Lei Fan1,2, Jiahui Mou1,2, Yue Yin4, Chao Peng5, Yuxiang Chen1, Henglei Lu1,6, Liting Zhao7, Zhouteng Tao1,2, Jing Chen1,2, Yizheng Wang8, Xinming Qi1,2, Ruimin Huang 2,9*, Jin Ren1,2*. MiR-629-5p promotes the invasion of lung adenocarcinoma via increasing both tumor cell invasion and endothelial cell Permeability. Oncogene. 2020 Apr; 39(17):3473-3488. (IF=7.971)

5.Y Xiao, M Ge, X Xue, C Wang, H Wang, X Wu, L Li, L Liu, X Qi, Y Zhang, Y Li, H Luo, T Xie, J Gu and J Ren*. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney International 2008,73(11): 1231-1239 (IF= 8.306)

6.Yiting Zhang127, Jianhua Sun17, Minjia Tan23, Yongzhen Liu1, Qian Li23, Hua Jiang4, Huamao Wang4, Zonghai Li4, Wei Wan25, Hualiang Jiang25, Henglei Lu1, Bingshun Wang6, Jin Ren12*, Likun Gong12*. Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys. Molecular Therapy. 6 June 2018, 26(6) , 1457-1470.  (IF= 8.402)

7.Pu M, Chen J, Tao Z, Miao L, Qi X, Wang Y, Ren J. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019 Feb;76(3):441-451.(IF= 7.014)

8.Yang Zhao, Xinming Qi, Jing Chen, Wenxin Wei, Cunzhi Yu, Hong Yan, Mengfan Pu, Yu Li, Lingling Miao, Chunzhu Li*, Jin Ren*. The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Cancer Letters.  2017 Nov 1;408:102-111. (IF=6.508)

9.Lingling Miao, Hailan Yao, Chenggang Li, Mengfan Pu, Xuan Yao, Hui Yang , Xinming Qi, Jin Ren*, YizhengWang*. A dual inhibition: microRNA-552 suppresses both transcription and translation of cytochrome P450 2E1. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms. 2016;1859(4):650-662. (IF=6.332)

10.Mengfan Pu, Chenggang Li, Xinming Qi, Jing Chen, Yizheng Wang, Lulu Gao, Lingling Miao*, Jin Ren*. MiR-1254 suppresses HO-1 expression through seed region-dependent silencing and non-seed interaction with TFAP2A transcript to attenuate NSCLC growth. PLoS Genetics. 2017 Jul 27;13(7):e1006896. doi: 10.1371. (IF=6.100)

11.Ma D, Jiang Y, Chen F, Gong LK, Ding K, Xu Y, Wang R, Ge A, Ren J*, Li J, Li J, Ye Q. Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. Journal of Medicinal Chemistry. 2006; 49 (2):456-458. (IF=6.054)

12.Yang Zhao, Jing Chen, Wenxin Wei, Xinming Qi, Chunzhu Li, and Jin Ren. The dual-inhibitory effect of miR-338-5p on multidrug resistance and cell growth of hepatocellular carcinoma. Signal Transduction and Targeted Therapy. 2018 Jan 26;3:3. doi: 10.1038. (IF=5.873)

13.Luan Y, Xing G, Qi X, Wu M, Li C, Yao J, Gong L, Nohmi T, Gu J, Zhou W, Zheng S, Ren J. The application of hepatic P450 reductase null gpt delta mice in studying the role of hepatic P450 in genotoxic carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mutagenesis. Arch Toxicol. 2012; 86(11): 1753-61. (IF=5.741)